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Corey J. Langer, MD, Matthew R. Smith, MD, PhD,¶ Janet E. Brown, MD,# and
Robert E. Coleman, MD, FRCP**
Introduction: Bone metastases from non-small cell lung cancer
(NSCLC) are associated with skeletal-related events (SREs) and
elevated levels of N-telopeptide of type I collagen (NTX) in some
patients. Zoledronic acid (ZOL) reduces SRE risk and NTX levels.
Methods: To assess effects of baseline variables, including NTX
levels (normal  NTX  64 nmol/mmol creatinine; high  NTX
 64 nmol/mmol creatinine), on treatment effects in NSCLC pa-
tients, a retrospective analysis was performed in NSCLC patients
with bone metastases (N  382) treated with ZOL or placebo every
3 weeks in a 21-month randomized clinical trial in patients with
NSCLC or other solid tumors. Cox proportional hazards models
assessed relative risks (RRs) of SREs, bone lesion progression, and
death. Multivariate models analyzed covariate effects on survival.
Results: For both placebo- and ZOL-treated patients, high baseline
NTX correlated with increased SRE risk (p  0.068 and 0.012,
respectively). Although high versus normal baseline NTX correlated
with more than twofold increased risks of bone lesion progression
and death in the placebo group (p  0.039 and 0.001, respectively),
correlations were weaker in the ZOL group (RR 1.38; p 0.0186
and RR  1.27; p  0.142, respectively), suggesting an interaction
effect of ZOL and baseline NTX. Among patients with high baseline
NTX, ZOL significantly reduced the RR of death by 35% versus
placebo (p  0.024). Per multivariate analysis, ZOL treatment (p 
0.005), higher lymphocyte count (p  0.011), performance status 0
to 1 (p  0.012), and absence of narcotic use (p  0.016) correlated
with improved survival.
Conclusions: This retrospective analysis revealed statistically sig-
nificant correlations between ZOL and increased survival versus
placebo in NSCLC patients and high baseline NTX levels.
Key Words: Bone markers, Non-small cell lung cancer, N-telopep-
tide of type I collagen, Survival, Zoledronic acid.
(J Thorac Oncol. 2008;3: 228–236)
Lung cancer is the most common cancer worldwide,1 andnon-small cell lung cancer (NSCLC) is the most prevalent
form of lung cancer.2,3 Advanced NSCLC is often highly symp-
tomatic,4 and an estimated 30 to 40% of patients develop bone
metastases.5 In these patients, skeletal complications can cause
considerable morbidity and may result in functional impairment
and loss of mobility. Increased tumor growth in bone can result
in increased tumor growth leading to potentially debilitating
skeletal-related events (SREs) such as pathologic fractures and
bone pain requiring palliative radiotherapy. These SREs are
clinically meaningful sequelae that are associated with increased
health care costs and decreased quality of life.6–8 Moreover,
pathologic fractures have been associated with a significantly
increased risk of death in patients with malignant bone disease
from multiple myeloma or bone metastases from breast cancer
or prostate cancer.9,10 Although no significant correlation was
observed in patients with lung cancer or other aggressive solid
tumors because of their short median time of survival in patients
enrolled in the trial, the extended survival of patients in this
setting with advances in primary therapies may increase the risk
of death in patients who experience a pathologic fracture. There-
fore, preventing SREs or delaying their onset might not only
improve quality of life but also potentially extend survival.
Interactions between tumor and bone typically result in
increased rates of bone metabolism, which can be detected by
increases in levels of biochemical markers of bone metabo-
lism.11,12 For example, serum bone-specific alkaline phospha-
tase (BALP) levels reflect ongoing levels of bone formation,
and N-telopeptide of type I collagen (NTX) is a sensitive
marker of osteolysis.11,12 Bone markers provide insight into
the extent or aggressiveness of bone metastases.11,13 In an
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exploratory analysis of the placebo-control arms of two phase
III trials of zoledronic acid, cancer patients with bone metas-
tases and elevated NTX levels ( 50 nmol/mmol creatinine)
were found to have approximately twofold increases in their
risk of SREs and bone disease progression and an approxi-
mately three- to fivefold increased risk of death compared
with patients with low NTX levels (p  0.01 for all).11
Similarly, compared with patients with low BALP levels,
patients with elevated BALP levels on study had significant
increases in their relative risks (RRs) of SREs and death.
Recent bone marker assessment results during bisphospho-
nate treatment have also been shown to have prognostic
significance.12
Bisphosphonates are inhibitors of bone resorption used
in the oncology setting for the prevention of SREs and
treatment of hypercalcemia of malignancy in patients with
bone metastases. Zoledronic acid (ZOMETA; Novartis Phar-
maceuticals Corporation, East Hanover, NJ; Novartis Pharma
AG, Basel, Switzerland) is the only bisphosphonate that has
demonstrated efficacy for the prevention of SREs in patients
with bone metastases from a wide range of solid tumors
including breast cancer, prostate cancer, and lung cancer.14–17
In a phase III, multicenter, randomized, placebo-controlled
trial, zoledronic acid (4 mg via 15-minute infusion every 3
weeks for up to 21 months) significantly delayed the onset
and reduced the ongoing risk of SREs compared with placebo
in patients with bone metastases secondary to lung cancer and
other aggressive solid tumors.15,16 Zoledronic acid also sig-
nificantly lowered NTX levels relative to baseline.12,16 Ap-
proximately one half of the enrolled patients had NSCLC,
and their 1-year survival rate was approximately 30%.15
However, correlations between baseline NTX levels and
outcomes have not been evaluated specifically in patients
with NSCLC using the currently accepted upper limit of normal
for NTX levels in oncology patients (i.e., 64 nmol/mmol creat-
inine), and prognostic models for survival in patients with bone
metastases from NSCLC are needed. Moreover, although sur-
vival was not a primary end point of this zoledronic acid study,
survival was approximately 1 month longer for zoledronic acid-
treated patients with NSCLC compared with placebo (not sta-
tistically significant).15
The current analysis was initiated to investigate
whether baseline bone marker levels had prognostic signifi-
cance in patients with NSCLC treated with zoledronic acid in
a phase III, randomized, placebo-controlled trial and whether
the nonsignificant survival increase with zoledronic acid
versus placebo in the overall NSCLC stratum was driven by
subsets of patients who may have benefited more than others
during treatment.15,16
PATIENTS AND METHODS
This was a retrospective analysis of patients with
NSCLC in a phase III, multicenter, randomized, placebo-
controlled trial of zoledronic acid in patients with bone
metastases from NSCLC or other solid tumors (not including
breast or prostate cancer).15,16 Details of the study design
have been previously published.15,16 A brief description is
provided herein.
Patients and Treatment
Patients with documented bone metastases secondary to
NSCLC or other solid tumors (excluding breast or prostate
cancer) were eligible for this trial. Baseline disease charac-
teristics, radiologic examinations, Eastern Cooperative On-
cology Group (ECOG) performance status, and serum and
urine chemistry values were assessed before the initiation of
treatment. Patients were randomized to receive zoledronic
acid (4 mg or 8 mg) or placebo via 15-minute infusion every
3 weeks for 9 months. Patients who completed this core phase
were offered to continue blinded treatment for another year.
The final analysis was performed at 21 months. After the
study was initiated, the 8-mg zoledronic acid dose was
reduced to 4 mg to ensure renal safety, and this group was
thereafter referred to as the zoledronic acid 8/4-mg group.
The majority of infusions in this group were administered at
the 4-mg dose level, and outcomes were similar between the
4-mg and the 8/4-mg treatment arms. Therefore, both
zoledronic acid groups are combined in the current analysis.
Previous analyses have been performed based on the com-
bined groups.12
Patients with NSCLC who were treated with either
zoledronic acid or placebo were included in the retrospective
analysis and were also analyzed according to baseline NTX
levels.
Clinical Endpoints
In the prospective trial, the proportion of patients with
an SRE was the primary end point.15,16 The SRE composite
end point is an objective measurement of clinically meaning-
ful skeletal morbidity.18 Survival is the primary outcome
evaluated in the current analyses because this is the ultimate
end point in oncology trials and is not affected by observation
bias. Bone lesion progression was also evaluated because it is
a variable that has been correlated with bone marker level
increases,19 although this end point was limited by the fre-
quency of radiologic assessment in the current database
(approximately every 3 months during the trial).15,16
Bone Markers
Baseline urinary NTX levels were assessed only in
patients treated in the United States or Canada. Urinary NTX
was measured by enzyme-linked immunosorbent assay, nor-
malized to urinary creatinine, and categorized according to
the following variables: low NTX,  64 nmol/mmol creati-
nine; high NTX,  64 nmol/mmol creatinine, based on the
upper limit of normal for disease-free premenopausal women.
Serum BALP levels were also measured by enzyme-linked
immunosorbent assay.
Statistical Analyses
Patients with NSCLC who had baseline NTX and
BALP assessments were included in the bone marker subset
analyses. Cox regression models were used to assess associ-
ations between bone marker levels and outcomes (e.g., SREs,
bone lesion progression, and death) and between bisphospho-
nate treatment and survival in patients with normal or high
NTX.20 Kaplan-Meier estimates were computed for the pro-
portion of patients alive over time by group.21 The cumulative
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probability of an on-study SRE was assessed using survival-
adjusted cumulative incidence functions because of the com-
peting risk of death. After the significant benefit of zoledronic
acid in the high NTX subset was identified, a series of
multivariate analyses to further investigate the effect were
preplanned and then executed.
Multivariate regression analyses were performed to
investigate the potential effects of baseline characteristics
and treatment effects on survival. For parameters without
an established cut-off value (e.g., the upper limit of nor-
mal), either the median for the specific population in the
model was used or the parameter was treated as a contin-
uous variable. The baseline variables included in each of
these models were treatment group (zoledronic acid 4 mg
or 8/4 mg versus placebo); sex; race; cancer duration; age
at study entry; weight at study entry; Functional Assess-
ment of Cancer Therapy-General (FACT-G) total score;
Brief Pain Inventory (BPI) composite pain score; SRE
history (yes/no); analgesic usage (none or minor analgesics
or coanalgesics versus narcotics); ECOG performance sta-
tus score; predominant lesion type; NTX status (normal or
high); BALP status (normal or  146 U/L); and the
following variables using the median (listed in parentheses
for the high-NTX subset) as a cut-off value: urinary NTX
level (102 nmol/mmol creatinine), serum creatinine (1
mg/dL), serum lactate dehydrogenase ([LDH] 246.5 U/L),
lymphocytes (14.025%; and as a continuous variable),
albumin (38 g/L; and as a continuous variable), and he-
moglobin (11.7 g/dL; and as a continuous variable). All
available baseline demographic and disease characteristics
data were included in the univariate and full multivariate
models to ensure that variables of unexpected significance
were captured in the reduced model. For generation of the
reduced model, the initial full model included only patients
for whom there was a complete data set for all variables to
minimize the confounding effect of correlated variables on
the model. The majority of patients who were not included
in this model were missing either NTX or BPI data.
To identify any significant interactions between treat-
ment and each baseline variable, multivariate models were
generated using the treatment group, the respective baseline
prognostic variable, and their interaction term. The multivar-
iate model included all baseline variables, and a reduced
model was generated by backward elimination until only
significant variables remained in the model; variables were
considered significant if p  0.05.
RESULTS
Baseline Characteristics for Patients with
NSCLC
In the phase III trial of zoledronic acid in patients with
lung cancer or other solid tumors, 382 patients with NSCLC
were randomized to zoledronic acid (n  259) or placebo (n 
123) (Table 1).15,16 Patient demographics and baseline disease
characteristics were similar between the treatment groups. A
total of 263 patients had baseline NTX assessments, and 144
(55%) had high baseline NTX levels. This subset had a lower
median time from the diagnosis of bone metastases to study
entry compared with the overall population.
TABLE 1. Patient Demographics and Baseline Disease Characteristics (Study 011)
Factor
NSCLC Patients (n  382) High-NTX Subset (n  144)
Zoledronic
Acid
(n  259)
Placebo
(n  123)
Zoledronic
Acid
(n  102)
Placebo
(n  42)
Median age, yr (range) 63 (37–88) 63 (39–82) 64 (37–88) 64 (43–82)
Sex, n (%)
Male 178 (68.7) 78 (63.4) 68 (66.7) 26 (61.9)
Female 81 (31.3) 45 (36.6) 34 (33.3) 16 (38.1)
Race, n (%)
White 230 (88.8) 112 (91.1) 88 (86.3) 36 (85.7)
Black/Asian/Other 29 (11.2) 11 (8.9) 14 (13.7) 6 (14.3)
ECOG PS 0 or 1, n (%) 214 (82.6) 110 (89.4) 86 (84.3) 36 (85.7)
BPI  3.25 U, n (%)a 104 (43.9) 52 (47.7) 40 (40.0) 15 (37.5)
SGOT  23.0 U, n (%)a 129 (50.0) 55 (45.8) 46 (45.1) 17 (40.5)
Previous SRE, n (%)a 174 (67.4) 91 (75.2) 73 (72.3) 35 (83.3)
NTX level, nmol/mmol creatinineb 84.8  68.5 77.8  45.2 119.14  75.1 107.88  41.9
Serum creatinine, mg/dLb 1.01  0.25 1.01  0.21 0.97  0.21 0.95  0.22
Baseline LDH  246.5 U/L, n (%)a 128 (49.6) 61 (50.8) 63 (61.8) 26 (61.9)
Baseline lymphocytes  14.025, n (%)a 126 (49.4) 61 (51.3) 60 (58.8) 25 (59.5)
Median time since diagnosis of bone
metastases, months
0.82 0.61 0.36 0.43
Data from the trials by Rosen et al.15,16
a Percentages were calculated using only those patients who had data for this parameter.
b Values reported as mean  standard deviation.
NSCLC, non-small cell lung cancer; NTX, N-telopeptide of type I collagen; ECOG, Eastern Cooperative Oncology Group; PS, performance status; BPI, Brief Pain Inventory;
U, unit; SGOT, serum glutamic-oxaloacetic transaminase; SRE, skeletal-related event; LDH, lactate dehydrogenase.
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Baseline NTX Levels and Risks of Clinical
Events
Among 80 patients in the placebo group who had
baseline NTX assessments, 42 (53%) had high levels. High
NTX was associated with a nonsignificant increased risk of
SREs (RR  1.64; p  0.068) and a first SRE (RR  1.49;
p  0.225) compared with normal baseline NTX (Fig. 1A).
Patients with high baseline NTX levels were at a significantly
increased risk of bone lesion progression (RR  2.15; p 
0.039) and death (RR  2.39; p  0.001) compared with the
subset of placebo-group patients who had normal baseline
NTX levels.
Among the 183 zoledronic acid-treated patients with
baseline NTX assessments, 102 (56%) had high levels. In
the zoledronic acid group, patients with high baseline NTX
had a significant 81% increased risk of any SRE (RR 
1.81; p  0.012) and a trend toward an increased risk of a
first SRE (RR  1.30; p  0.287) compared with patients
with normal NTX at baseline. In contrast with the results
in the single placebo group, high baseline NTX was not
associated with significant increases in the risks of bone
lesion progression or death among zoledronic acid-treated
patients (p  0.186 and 0.142, respectively; Fig. 1B),
despite the larger sample size that resulted from combining
the two treatment groups.
Skeletal Morbidity and Overall Survival
Among all patients with NSCLC, zoledronic acid sig-
nificantly reduced the risk of a first on-study SRE versus
placebo (p  0.028; Fig. 2). Andersen-Gill multiple event
analysis, which accounts for all SREs and for the timing of
SREs, revealed a significant 38% reduction in the risk of
developing SREs for the zoledronic acid groups compared
with the placebo group (RR  0.62; p  0.001). There were
no significant differences in time to bone lesion progression
between groups. Radiologic assessments mandated by the
study, however, were only performed approximately every 3
months unless clinically indicated.
Median survival after study entry was 177 days for
patients with NSCLC. Patients with NSCLC treated with
zoledronic acid lived approximately 1 month longer than
those in the placebo group, but this difference was not
statistically significant (median survival, 187 days for
zoledronic acid versus 157 days for placebo; p  0.539).
Based on the observations regarding survival and the weaker
prognostic significance of high baseline NTX levels among
patients who were treated with zoledronic acid versus pla-
cebo, the effects of baseline NTX levels on zoledronic acid
treatment benefits were examined.
Analysis by N-Telopeptide Level in Patients
with NSCLC
Subset analyses were performed on the 262 patients
who had baseline NTX assessments. Statistical heterogeneity
for the treatment effect of zoledronic acid on survival be-
tween the high and low NTX groups was detected (p 
0.018), suggesting that these two groups were different and
that inferences regarding possible treatment effects should be
made separately for them. In the group of 118 patients who
had normal baseline NTX levels, the Kaplan-Meier survival
curves (Fig. 3A) and risk of death were similar for the
zoledronic acid-treatment groups compared with placebo
(RR 1.326; p 0.223). In contrast, among the 144 patients
with high baseline NTX levels, zoledronic acid and placebo
groups had significantly different Kaplan-Meier survival
curves (Fig. 3B), and zoledronic acid significantly reduced
the risk of death by 35% compared with placebo (RR 
0.652; p  0.025). Further assessments were performed on
the high-NTX subset to investigate factors that might have
contributed to the survival differences between the zoledronic
acid and placebo groups.
In the high-NTX subgroup, the majority of patients
(85%) in both the treatment and placebo groups had an
ECOG performance status of 0 or 1, approximately one half
of the patients were  65 years of age, and characteristics were
well balanced between the treatment groups (Table 1).15,16
Moreover, the percentage of patients receiving concomitant
chemotherapy was similar between patients who had high
NTX levels and the overall patient population in each treat-
ment group. Approximately 80% of all patients receiving
zoledronic acid and patients with elevated NTX levels receiv-
ing zoledronic acid also received chemotherapy. Similarly,
76% of all placebo-treated patients and placebo-treated patients
with elevated NTX levels were receiving chemotherapy.
FIGURE 1. Relative risk of on-study skeletal complications,
disease progression, or death for patients with non-small cell
lung cancer and high N-telopeptide of type 1 collagen
(NTX) levels (defined as  64 nmol/mmol creatinine) versus
low NTX levels ( 64 nmol/mmol creatinine) treated with
(A) placebo or (B) zoledronic acid (4 mg  8/4 mg), by uni-
variate analysis. Length of horizontal line represents the 95%
confidence interval. SRE, skeletal-related event.
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Analysis of Baseline Covariates and Treatment
Effects on Survival (Overall)
For the overall population of patients with NSCLC and
bone marker assessments, 12 baseline variables were found to
significantly correlate with improved survival in univariate
models: high FACT-G total score; lower BPI composite pain
score; female sex; no baseline requirement for narcotic pain
medication; ECOG performance status of 0 or 1; normal NTX
status; normal BALP status; serum creatinine  1.0 mg/dL;
absolute lymphocyte count; and serum glutamic-oxaloacetic
transaminase, albumin, and LDH below the median value.
However, after adjustment in a multivariate model, NTX and
BALP status and levels of creatinine, serum glutamic-oxaloa-
cetic transaminase, and lymphocytes decreased in prognostic
significance, and treatment with zoledronic acid showed a
trend toward a survival benefit compared with placebo (RR
0.765; p  0.103).
The effects of baseline covariates on the association
between treatment groups and survival were assessed in two
multivariate models (Table 2). The first of these included all
patients with information for each of the respective baseline
variables (the number of patients contributing to these anal-
yses differs depending on variable), and the second included
only patients with a complete set of data for every variable
(n  244). In both models, survival benefits with zoledronic
acid treatment significantly varied by race, ECOG perfor-
mance status, and baseline NTX level variables. In the second
analysis, baseline LDH status emerged as a covariable that
profoundly affected the survival benefit. In a reduced multi-
variate model involving patients with complete data (n 
244), adjusting for the effects of FACT-G total score, nar-
FIGURE 2. Proportion of patients with non-small cell lung cancer who experienced  1 on-study skeletal-related event (SRE).
FIGURE 3. Survival patterns of patients with non-small cell
lung cancer, based on N-telopeptide of type 1 collagen
(NTX) levels at baseline. A Kaplan-Meier survival curves for
patients with normal baseline NTX. B Kaplan-Meier survival
curves for patients with elevated baseline NTX. RR, relative
risk; CI, confidence interval.
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cotics use, ECOG performance status, SRE history, baseline
lymphocyte, and baseline albumin levels, baseline LDH level
significantly influenced the survival effect of zoledronic acid
(p  0.005 for LDH above versus below the median value
[e.g., the test of treatment benefit by covariate interaction]).
Zoledronic acid produced an approximately 2.4-fold decrease
in risk of death versus placebo in patients with elevated LDH
(p  0.0015), and a nonsignificant 4.3% increase in the low
LDH patients (p  0.823). In the reduced multivariate model
investigating the effects of LDH level on treatment benefits,
only FACT-G score, narcotics use, ECOG performance sta-
tus, prior SRE, baseline lymphocyte, and albumin levels were
significant covariates for a survival effect of zoledronic acid,
whereas NTX was not a significant covariate.
Analysis of Baseline Covariates and Treatment
Effects on Survival (High NTX)
In univariate models in the high-NTX subset, the fol-
lowing covariates significantly correlated with improved sur-
vival: treatment with zoledronic acid versus placebo, higher
FACT-G total score, no baseline requirement for narcotic
pain medication, ECOG performance status of 0 or 1, and
higher than the median lymphocyte level (Table 3). However,
after adjustment in a multivariate model, only treatment with
zoledronic acid versus placebo, higher FACT-G total score,
and no requirement for narcotic pain medication remained
significant. The reduced multivariate model showed that
zoledronic acid was associated with a statistically significant
43% reduction in the risk of death compared with placebo
(RR  0.565; p  0.0047). Therefore, this multivariate
model confirmed the survival benefit for zoledronic acid
versus placebo that was observed in the initial analyses in the
high-NTX subset.
Similar to the analyses performed in the overall popu-
lation of patients with NSCLC, the effects of baseline covari-
ates on the survival benefit of zoledronic acid were analyzed
in two multivariate models in the high baseline-NTX subset
(Table 4). In both models, survival effects from treatment
were found to vary significantly based on age, race, serum
LDH level, and NTX level relative to the median for the
high-NTX group (102.0 nmol/mmol creatinine). The survival
benefit in patients treated with zoledronic acid was greatest
among patients with a shorter time since their primary cancer
diagnosis, younger age, and less profound NTX elevations.
The current analysis was designed to investigate differ-
ences in treatment effects based on patients’ bone marker
levels; however, other significant covariates for treatment
effects were identified, including race, performance status,
and LDH level. Further analyses are underway to investigate
how the significant covariates associated with improved sur-
vival with zoledronic acid treatment versus placebo interact,
especially in regard to LDH status.
DISCUSSION
Zoledronic acid is the only bisphosphonate to be ap-
propriately evaluated in the treatment of both osteolytic and
osteoblastic bone metastases secondary to a broad range of
tumors, including NSCLC, and has been shown to signifi-
cantly reduce the incidence and rate of skeletal complica-
tions.15,16 In addition to prevention of SREs and palliative
effects on bone pain,22–24 the analyses presented herein sug-
TABLE 2. Multivariate Model with Treatment Effect, Baseline Prognostic Variable, and Their Interaction Term
Covariatea Domain
Patients with Respective Variable Patients with All Variables (n  244)
n RR 95% CI p pb n RR 95% CI p pb
BPI score 3.25 units 156 1.159 (0.797–1.686) 0.441 0.065 108 1.084 (0.684–1.719) 0.732 0.371
3.25 units 190 0.726 (0.525–1.004) 0.053 136 0.823 (0.558–1.215) 0.327
Race White 342 1.001 (0.784–1.279) 0.993 0.018 216 1.043 (0.761–1.428) 0.794 0.011
Black/Asian/Other 40 0.391 (0.187–0.818) 0.013 28 0.291 (0.115–0.733) 0.009
ECOG PS Active 324 0.947 (0.737–1.217) 0.670 0.048 213 0.990 (0.719–1.362) 0.950 0.039
Some impairment 57 0.477 (0.254–0.898) 0.022 31 0.391 (0.172–0.890) 0.025
NTX status 64.0 118 1.340 (0.852–2.106) 0.205 0.020 109 1.344 (0.838–2.154) 0.220 0.024
64.0 145 0.672 (0.465–0.971) 0.034 135 0.667 (0.454–0.979) 0.039
Serum LDH 246.5 189 1.119 (0.799–1.566) 0.513 0.136 169 1.241 (0.863–1.785) 0.245 0.001
246.5 189 0.783 (0.566–1.084) 0.141 75 0.342 (0.201–0.583) 0.001
Lymphocytes 14.025% 187 0.896 (0.648–1.239) 0.507 0.677 131 0.620 (0.417–0.923) 0.019 0.026
14.025% 187 0.991 (0.704–1.394) 0.957 113 1.231 (0.783–1.936) 0.368
SGOT 23.0 184 1.044 (0.737–1.479) 0.808 0.468 109 1.266 (0.788–2.034) 0.330 0.119
23.0 194 0.877 (0.639–1.204) 0.417 135 0.780 (0.531–1.144) 0.203
Albumin 38 180 0.779 (0.570–1.120) 0.193 0.279 102 0.649 (0.406–1.038) 0.071 0.104
38 197 1.035 (0.749–1.432) 0.834 142 1.075 (0.731–1.581) 0.713
a The following covariates showed no trends for treatment by covariate interactions in either model (p  0.15): Cancer duration 5 vs. 5 mo; age 63 vs. 63 yr; weight
71 vs. 71 kg; Functional Assessment of Cancer Therapy-General total score 70 vs. 70; sex; narcotics use; lesion type; prior skeletal-related event; bone-specific alkaline
phosphatase 64 vs. 64 U/L; serum creatinine 1 vs. 1 mg/dL.
b Test of treatment by covariate interaction.
RR, relative risk; CI, confidence interval; BPI, Brief Pain Inventory composite score; ECOG, Eastern Cooperative Oncology Group; PS, performance status score; NTX, urinary
N-telopeptide of type I collagen in nmol/mmol creatinine; LDH, lactate dehydrogenase, in g/L; SGOT, serum glutamic-oxaloacetic transaminase; Albumin, in g/L.
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gest that zoledronic acid may offer additional benefits in
NSCLC patients who have high NTX levels at baseline.
In the current analysis, zoledronic acid treatment was
associated with significantly improved survival compared
with placebo in patients with high baseline NTX, whereas
survival was comparable between groups in the low-NTX
subset. Although the reasons for this are not clear, it is
possible that patients with high NTX may have an especially
responsive pathophysiology in bone or more likely may have
a greater propensity to benefit from early therapy because of
their initial higher risk status for potentially life-limiting
SREs. This is consistent with the large-scale correlative
TABLE 3. Cox Regression Analysis of Correlations Between Baseline Variables and Treatment and Survival Outcomes (High
NTX Population)
Covariate
Univariate Reduced Multivariate
RR 95% CI p RR 95% CI p
Treatment, ZOL vs. PLA 0.657 (0.447–0.967) 0.033 0.565 (0.381–0.840) 0.005
Cancer duration, per 1-yr 1 1.039 (0.956–1.129) 0.370
Age, per 1-yr 1 1.008 (0.990–1.026) 0.406
FACT-G score, per 1-unit 1 0.985 (0.973–0.996) 0.008
BPI score, per 1-unit 1 1.066 (0.983–1.156) 0.123
Race, Black/Asian/Other vs. White 0.635 (0.374–1.077) 0.092
Mild/Strong narcotics vs none 1.797 (1.144–2.823) 0.011 1.757 (1.110–2.780) 0.016
ECOG PS: 2 vs. 0 or 1 1.971 (1.186–3.276) 0.009 1.941 (1.158–3.255) 0.012
Prior SRE 1.174 (0.778–1.772) 0.444
NTX  64.0 1.263 (0.885–1.801) 0.198
BALP  146.0 1.004 (0.688–1.465) 0.983
Lymphocytes, per 1% 1 0.974 (0.957–0.992) 0.004 0.977 (0.960–0.995) 0.011
LDH  246.5 1.199 (0.830–1.732) 0.334
Albumin, per 1-unit 1 0.957 (0.913–1.003) 0.065
RR, relative risk; CI, confidence interval; ZOL, zoledronic acid; PLA, placebo;1, increase; FACT-G, Functional Assessment of Cancer Therapy-General total score; BPI, Brief
Pain Inventory composite score; vs, versus; ECOG, Eastern Cooperative Oncology Group; PS, performance status score; SRE, skeletal-related event; NTX, urinary N-telopeptide of
type I collagen, in nmol/mmol creatinine; BALP, bone-specific alkaline phosphatase, in U/L; LDH, lactate dehydrogenase, in g/L; albumin, in g/L.
TABLE 4. Multivariate Model with Treatment Effect, Baseline Prognostic Variable, and Their Interaction Term (High NTX
Population)
Covariatea Domain
Patients with Respective Variable Patients with All Variables (n  135)
n RR 95% CI p pb n RR 95% CI p pb
Cancer duration 5.02 mo 77 0.462 (0.273–0.784) 0.004 0.107 70 0.438 (0.252–0.763) 0.004 0.078
5.02 mo 67 0.853 (0.502–1.449) 0.557 65 0.878 (0.511–1.509) 0.639
Age 63 yr 63 0.403 (0.221–0.732) 0.003 0.043 58 0.386 (0.208–0.718) 0.003 0.035
63 yr 81 0.886 (0.550–1.429) 0.621 77 0.904 (0.551–1.482) 0.689
Race White 124 0.791 (0.528–1.183) 0.254 0.014 116 0.803 (0.530–1.218) 0.302 0.009
Other 20 0.201 (0.073–0.552) 0.002 19 0.173 (0.059–0.505) 0.001
Narcotics used None 29 1.115 (0.462–2.694) 0.809 0.120 29 1.115 (0.461–2.693) 0.809 0.113
Mild/strong 114 0.514 (0.338–0.781) 0.002 106 0.502 (0.325–0.778) 0.002
NTX 102.0 71 0.964 (0.577–1.609) 0.887 0.001 68 0.950 (0.562–1.605) 0.847 0.002
102.0 73 0.270 (0.152–0.479) 0.001 67 0.263 (0.144–0.482) 0.001
BALP 146.0 47 0.988 (0.495–1.971) 0.972 0.146 44 1.040 (0.505–2.139) 0.916 0.123
146.0 97 0.537 (0.344–0.839) 0.006 91 0.530 (0.335–0.840) 0.007
LDH 246.5 89 0.843 (0.526–1.351) 0.478 0.030 84 0.883 (0.537–1.450) 0.622 0.022
246.5 55 0.356 (0.191–0.661) 0.001 51 0.345 (0.183–0.650) 0.001
Hemoglobin 11.70 77 0.454 (0.269–0.767) 0.003 0.075 73 0.476 (0.278–0.815) 0.007 0.121
11.70 67 0.892 (0.525–1.515) 0.672 62 0.876 (0.503–1.528) 0.641
a The following covariates showed no trends for treatment by covariate interactions in either model (p  0.15): Functional Assessment of Cancer Therapy-General total score
70 vs. 70; Brief Pain Inventory composite score 3.25 vs. 3.25; sex; Eastern Cooperative Oncology Group performance status score active vs. some impairment; prior
skeletal-related event; lesion type; creatinine 1 vs. 1 mg/dL; lymphocytes 14.025% vs. 14.025%; serum glutamic-oxaloacetic transaminase 23 vs. 23 U/L; serum albumin
38 g/L vs. 38 g/L.
b Test of treatment by covariate interaction.
NTX, urinary N-telopeptide of type I collagen, in nmol/mmol creatinine; RR, relative risk; CI, confidence interval; BALP, bone-specific alkaline phosphatase, in U/L; LDH,
lactate dehydrogenase, in g/L.
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report of bone marker levels and outcomes in patients with
solid tumors (including NSCLC) published by Brown et al.12
in which recent bone marker assessments were found to better
correlate with risk of SREs and death compared with baseline
levels. Moreover, in a recent report in the breast cancer
setting, patients with high baseline NTX levels that normal-
ized during zoledronic acid treatment were reported to have
longer survival compared with patients whose NTX levels
remained persistently elevated.25 Conversely, patients with
normal NTX at baseline are at a lower risk for SREs, and their
clinical course and survival prospects are more likely to be
driven by extraskeletal disease.
Although the current analyses were exploratory in na-
ture, reduced mortality in zoledronic acid-treated patients
versus those who received placebo could be the result of
multiple effects that have been reported in previous clinical
trials and preclinical assessments. For example, zoledronic
acid reduces the risk of potentially life-limiting SREs.15,16 In
phase III clinical trials in which bisphosphonates have re-
duced the risk of SREs, survival was often longer with
bisphosphonate treatment versus placebo, although these dif-
ferences have seldom reached statistical significance.26–29
There is also preclinical evidence that zoledronic acid can
impede tumor growth, both overall and within the bone
microenvironment.30–36 The relative contributions of each of
these effects to the overall survival benefit remains undeter-
mined and may vary based on tumor type and other disease
characteristics.
Although the subset of patients with NSCLC who had
bone marker assessments was not a randomized cohort in
these retrospective analyses, all baseline covariates were
included in a complex multivariate model from which the
least significant variables were removed in stepwise fashion
to achieve a reduced multivariate model. In the overall
population of patients with NSCLC who had bone marker
assessments, multiple factors correlated with survival. How-
ever, among the patients with high NTX levels, only
zoledronic acid treatment, requirement for no more than mild
analgesics, good performance status, absence of severe lym-
phopenia, and normal LDH status correlated with improved
survival. Of these variables, zoledronic acid treatment com-
pared with placebo was associated with improved survival
and constitutes the only factor that can easily be changed by
the treating physician.
In the current analyses, survival benefits appeared most
profound in patients with factors that were associated with
less advanced disease or bone lesions (e.g., shorter cancer
duration and elevated NTX that has not reached extremely
high levels). Elevated LDH, a known indicator of poor
prognosis in NSCLC,37 was found to be linked not only with
reduced survival but with a reduced likelihood of experienc-
ing a survival benefit from zoledronic acid compared with
placebo. These findings suggest that zoledronic acid treat-
ment of bone metastases early during the course of disease
progression may be the optimum strategy. However, it must
be noted that the current indication for zoledronic acid is for
the prevention of SREs from bone metastases, and all patients
with bone metastases are considered at risk for SREs regard-
less of their overall disease state or performance status.
Currently, a phase III prospective study is ongoing to
evaluate the efficacy of zoledronic acid in delaying or pre-
venting bone metastases in patients with stage III NSCLC.
The results of this trial in patients with earlier stages of cancer
may underscore the importance of bone-directed therapies
even in patients without established bone lesions. The current
study has elevated the importance of treating bone metastases
in patients with high-risk disease.
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